Department of Value Based Healthcare, St. Antonius Hospital, Nieuwegein, The Netherlands; Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Urology. 2021 Jan;147:205-212. doi: 10.1016/j.urology.2020.08.089. Epub 2020 Oct 28.
To assess the impact of multiparametric magnetic resonance imaging (mp-MRI) local tumor staging on prostate cancer risk stratification and choice of treatment.
Prostate cancer patients, newly diagnosed from 2017 to 2018 at 7 Dutch teaching hospitals were included. Risk group classification was done twice, using either digital rectal examination (DRE) or mp-MRI information. Risk group migration and rates of treatment intensification associated with mp-MRI upstaging were established. Diagnostic accuracy measures for the detection of nonorgan-confined disease (stage ≥T3a), for both DRE and mp-MRI, were assessed in patients undergoing robot-assisted radical prostatectomy.
A total of 1683 patients were included. Upstaging due to mp-MRI staging occurred in 493 of 1683 (29%) patients and downstaging in 43 of 1683 (3%) patients. Upstaging was associated with significant higher odds for treatment intensification (odds ratio [OR]: 3.5 95% confidence interval [CI] 1.9-6.5). Stage ≥T3a on mp-MRI was the most common reason for risk group upstaging (77%). Sensitivity for the detection of stage ≥T3a was higher for mp-MRI compared to DRE (51% vs 12%, P <.001), whereas specificity was lower (82% vs 97%, P <.001). Mp-MRI resulted in a significantly higher cumulative rate of true positive and true negative stage ≥T3a predictions compared with DRE (67% vs 58%, P <.001).
Use of mp-MRI tumor stage for prostate cancer risk classification leads to upstaging in 1 of 3 patients. Mp-MRI enables superior detection of nonorgan-confined disease compared with DRE, and should be the preferred tool for determining clinical tumor stage.
评估多参数磁共振成像(mp-MRI)局部肿瘤分期对前列腺癌风险分层和治疗选择的影响。
纳入 2017 年至 2018 年期间 7 家荷兰教学医院新诊断的前列腺癌患者。使用直肠指检(DRE)或 mp-MRI 信息两次进行风险组分类。确定与 mp-MRI 升级相关的风险组迁移和治疗强化率。评估了在接受机器人辅助根治性前列腺切除术的患者中,DRE 和 mp-MRI 检测非器官受限疾病(≥T3a 期)的诊断准确性。
共纳入 1683 例患者。1683 例患者中,493 例(29%)因 mp-MRI 分期而升级,43 例(3%)因 mp-MRI 分期而降级。升级与治疗强化的可能性显著增加相关(优势比[OR]:3.5,95%置信区间[CI]:1.9-6.5)。mp-MRI 上的≥T3a 期是风险组升级最常见的原因(77%)。mp-MRI 检测≥T3a 期的敏感性高于 DRE(51%比 12%,P<.001),而特异性较低(82%比 97%,P<.001)。与 DRE 相比,mp-MRI 导致真阳性和真阴性≥T3a 期预测的累积率显著增加(67%比 58%,P<.001)。
使用 mp-MRI 肿瘤分期对前列腺癌风险分类导致 1/3 的患者升级。mp-MRI 可提高对非器官受限疾病的检测能力,优于 DRE,应成为确定临床肿瘤分期的首选工具。